Gene Therapies for Neurodegenerative Diseases May Need Only Phase 1 Trials, FDA Guidance Says
May 4, 2021
Because of how difficult it is to find participants for rare neurodegenerative disease trials, the FDA says in a recent draft guidance that phase 1 trials of gene therapies for such diseases may be sufficient to produce evidence for regulatory submissions.